News Sentiment

IONS sentiment intelligence

Ionis Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 46 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 54.39 Week of 17 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-6.6% over one week, -26.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Ionis Pharmaceuticals (IONS) Proxy filing Summary

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -6.6% Price reacting lower
Trend fit Trend inactive -26.6% over four weeks
Fair value 7.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 27
Negative 18

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
simplywall.st 9
Market source 8
Trefis 5
Business Wire 3
Quartr 2
Investing.com 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 14
Regulatory and legal 11
Analyst action 3
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Moomoo Direct company coverage

RBC Cuts Price Target on Ionis Pharmaceuticals to $85 From $100, Keeps Outperform Rating

RBC Capital Markets has reduced its price target for Ionis Pharmaceuticals (IONS) to $85 from $100, while maintaining an Outperform rating on the stock. This adjustment reflects a revised valuation perspective for the biotechnology company.

Tone
Negative 36/100
Event
Analyst action
Published
13 Jul 2026 11:40
Source
Moomoo
Stock Titan Direct company coverage

New Ionis RNA drug ION337 enters first human test in Dravet syndrome

Ionis Pharmaceuticals has initiated its Phase 1-2 ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome, a severe neurological disorder. This marks the first human participant dosed with ION337, which utilizes Ionis' advanced NMA technology designe

Tone
Positive 72/100
Event
Regulatory and legal
Published
13 Jul 2026 11:12
Source
Stock Titan
Sahm Direct company coverage

Ionis Pharmaceuticals (IONS) Faces A Key Setback As Eplontersen Misses In Phase 3

Ionis Pharmaceuticals and AstraZeneca announced that their Phase 3 trial for eplontersen in transthyretin mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, posing a significant setback for one of Ionis's key late-stage programs. Although the trial showed

Tone
Negative 28/100
Event
Market update
Published
12 Jul 2026 19:12
Source
Sahm
Quartr Direct company coverage

Ionis Pharmaceuticals (IONS) Status Update Summary

Ionis Pharmaceuticals (IONS) has transitioned from a partner-focused model to a fully integrated commercial-stage biotech, emphasizing independent drug launches and commercialization. The company has achieved three transformational medicine approvals, including Tryngolza, and has

Tone
Positive 74/100
Event
Market update
Published
10 Jul 2026 22:39
Source
Quartr
24/7 Wall St. Direct company coverage

Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up

Ionis Pharmaceuticals (IONS) experienced a significant intraday drop of 9%, bringing its weekly decline to over 25%, following the failure of its Phase 3 CARDIO-TTRansform study for eplontersen. This clinical setback for a key value driver negatively impacted the company and its

Tone
Negative 18/100
Event
Market update
Published
10 Jul 2026 17:37
Source
24/7 Wall St.
Benzinga Direct company coverage

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis Pharmaceuticals and AstraZeneca's Phase 3 CARDIO-TTRansform study for eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint. The trial's failure, where adding eplontersen did not significantly improve outcomes ov

Tone
Negative 28/100
Event
Market update
Published
10 Jul 2026 15:09
Source
Benzinga